S2B Syn2bio S.A.
Syn2bio S.A. operates as a biotechnology company. It engages in the development and commercialization of SYN2 cardiotracer, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. It is also engages in the research of new pharmaceutical compounds and its further study, registration, and market launch as a medicinal product. Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.…
Industry Peers
BiotechnologyKey Statistics
About Syn2bio (WSE: S2B)
›
Syn2bio (WSE: S2B) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 53.98 PLN on 20 November 2026. Its 52-week range is 26.20 PLN to 96.60 PLN: the price is 44.1% below the high and 106.0% above the low.
Its market capitalisation is 483.59M PLN.
Syn2bio reports return on equity of -141.9% and an operating margin of 0.0%.
Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 31.00 PLN is 42.6% below the current price.